Microwave ablation for treating small kidney and liver tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on the efficacy and safety of microwave ablation (MWA) for patients with primary and secondary liver malignancies and small renal tumors. It will evaluate the short, medium, and long-term clinical outcomes of patients undergoing MWA, comparing these results with existing literature on other treatment methods. Participants will continue their usual clinical care while data on their treatment and outcomes will be collected for analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \> 18 years with primary or secondary liver tumors or small kidney tumors that are not candidates for surgery or cannot be radically resected by surgery alone
* Primary liver cancer: up to three liver nodules ≤ 3 cm
* Secondary hepatic tumours: up to nodules ≤ 3 cm provided that the objective is complete hepatic clearance Renal tumours: single or multiple (von Hippel Lindau syndrome), \< 4 cm

Exclusion Criteria:

* pregnant women
* non-manageable coagulopathies
* Extended extrahepatic or extrarenal disease
* for liver ablation: presence of bilio-digestive anastomosis

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Francesco De Cobelli, MD
• Email: decobelli.francesco@hsr.it
• Phone: +390226432529

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer

  This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07123090

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.